NCT02583919 - Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 15, 2016

Study Completion Date

May 11, 2017

Conditions

Type 2 Diabetes

Interventions

DRUG

ISIS-GCGRRx- Dose Level 1

once weekly dosing for 26 weeks

DRUG

ISIS-GCGRRx- Dose Level 2

once weekly dosing for 26 weeks

DRUG

Placebo

once weekly dosing for 26 weeks

Trial Locations (19)

10016

Ionis Investigational Site, New York

20745

Ionis Investigational Site, Oxon Hill

27410

Ionis Investigational Site, Greensboro

28557

Ionis Investigational Site, Morehead City

29303

Ionis Investigational Site, Spartanburg

30060

Ionis Investigational Site, Marietta

32127

Ionis Investigational Site, Port Orange

45219

Ionis Investigational Site, Cincinnati

45245

Ionis Investigational Site, Cincinnati

77036

Ionis Investigational Site, Houston

77074

Ionis Investigational Site, Houston

77450

Ionis Investigational Site, Katy

90057

Ionis Investigational Site, Los Angeles

90255

Ionis Investigational Site, Huntington Park

91942

Ionis Investigational Site, La Mesa

91978

Isis Investigational Site, Spring Valley

94904

Ionis Investigational Site, Greenbrae

97404

Ionis Investigational Site, Eugene

98502

Ionis Investigational Site, Olympia